Assessment of HER2 testing patterns, HER2+ disease, and the utilization of HER2-directed therapy in early breast cancer

Breast Cancer: Targets and Therapy

Volumn 6, Issue , 2014, Pages 169-177

  Stenehjem, David D ^a,b   Yoo, Minkyoung ^a   Unni, Sudhir K ^a   Singhal, Mukul ^a   Bauer, Hillevi ^a   Saverno, Kim ^a   Quah, Cheng ^c   Masaquel, Anthony ^c   Brixner, Diana I ^a,d  

^a UNIVERSITY OF UTAH   (United States)

^b UNIVERSITY OF UTAH   (United States)

^c 3Genentech Inc   (United States)

^d UNIVERSITY OF UTAH   (United States)

Author keywords

Early stage breast cancer; FISH; HER2; HER2 targeted therapy; Human epidermal growth factor receptor 2; Immunohistochemistry

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER GRADING; CANCER RECURRENCE; CANCER STAGING; CHARLSON COMORBIDITY INDEX; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MIDDLE AGED; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; VERY ELDERLY;

EID: 84924871847     PISSN: None     EISSN: 11791314     Source Type: Journal    
DOI: 10.2147/BCTT.S69416     Document Type: Article

References (29)

1. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Fort Washington, PA: National Comprehensive Cancer Network; 2014. Available from: http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed June 10, 2014.
2. Wolff AC, Hammond ME, Schwartz JN, et al; American Society of Clinical Oncology/College of American Pathologists. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med. 2007;131(1):18-43.
3. College of American Pathologists. ASCO-CAP HER2 Test Guideline Recommendations: Summary of Guideline 2007 and 2013 Recommendations. Northfield, IL: College of American Pathologists; 2013. Available from: http://www.cap.org/apps/docs/committees/immunohistochemistry/summary_of_recommendations.pdf. Accessed September 18, 2014.
4. Clay MR, Iberri DJ, Bangs CD, Cherry A, Jensen KC. Clinicopathologic characteristics of HER2 FISH-ambiguous breast cancer at a single institution. Am J Surg Pathol. 2013;37(1):120-127.
5. Moja L, Tagliabue L, Balduzzi S, et al. Trastuzumab containing regimens for early breast cancer. Cochrane Database Syst Rev. 2012;4: CD006243.
6. Mitri Z, Constantine T, O'Regan R. The HER2 receptor in breast cancer: pathophysiology, clinical use, and new advances in therapy. Chemother Res Pract. 2012;2012:743193.
7. Dekker TJ, Borg ST, Hooijer GK, et al. Determining sensitivity and specificity of HER2 testing in breast cancer using a tissue micro-array approach. Breast Cancer Res. 2012;14(3):R93.
8. Gown AM. Current issues in ER and HER2 testing by ICH in breast cancer. Mod Pathol. 2008;21 Suppl 2:S8-S15.
9. Wolff AC, Hammond ME, Hicks DG, et al; American Society of Clinical Oncology; College of American Pathologists. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. Arch Pathol Lab Med. 2014;138(2):241-256.
10. Wolff AC, Hammond ME, Hicks DG, et al; American Society of Clinical Oncology; College of American Pathologists. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013;31(31): 3997-4013.
11. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25(1):118-145.
12. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-383.
13. Cronin KA, Harlan LC, Dodd KW, Abrams JS, Ballard-Barbash R. Population-based estimate of the prevalence of HER-2 positive breast cancer tumors for early stage patients in the US. Cancer Invest. 2010;28(9):963-968.
14. Parise CA, Bauer KR, Brown MM, Caggiano V. Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004. Breast J. 2009;15(6):593-602.
15. Barron JJ, Cziraky MJ, Weisman T, Hicks DG. HER2 testing and subsequent trastuzumab treatment for breast cancer in a managed care environment. Oncologist. 2009;14(8):760-768.
16. Bast RC Jr, Ravdin P, Hayes DF, et al; American Society of Clinical Oncology Tumor Markers Expert Panel. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2001;19(6):1865-1878.
17. Goddard KA, Bowles EJ, Feigelson HS, et al. Utilization of HER2 genetic testing in a multi-institutional observational study. Am J Manag Care. 2012;18(11):704-712.
18. Parise CA, Bauer KR, Caggiano V. Variation in breast cancer subtypes with age and race/ethnicity. Crit Rev Oncol Hematol. 2010;76(1): 44-52.
19. Fehrenbacher L, Habel LA, Capra AM, Anthony A, Li X. Incidence, demographic and tumor characteristics of HER2-positive invasive breast cancer in a large, unselected population, 2000-2006. Cancer Research. 2009;69(24): Supplement 3.
20. Konecny G, Pauletti G, Pegram M, et al. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J Natl Cancer Inst. 2003;95(2):142-153.
21. Viale G. Controversies in testing for HER2. American Society of Clinical Oncology 2011 Educational Book. 47th Annual Meeting; June 3-7, 2011; Chicago, IL. Alexandria, VA: American Society of Clinical Oncology; 2011.
22. Schalper KA, Kumar S, Hui P, Rimm DL, Gershkovich P. A retrospective population-based comparison of HER2 immunohistochemistry and fluorescence in situ hybridization in breast carcinomas: impact of 2007 American Society of Clinical Oncology/College of American Pathologists criteria. Arch Pathol Lab Med. 2014;138(2):213-219.
23. Shah SS, Ketterling RP, Goetz MP, et al. Impact of American Society of Clinical Oncology/College of American Pathologists guideline recommendations on HER2 interpretation in breast cancer. Hum Pathol. 2010;41(1):103-106.
24. Curigliano G, Viale G, Bagnardi V, et al. Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer. J Clin Oncol. 2009;27(34):5693-5699.
25. Gonzalez-Angulo AM, Litton JK, Broglio KR, et al. High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol. 2009;27(34):5700-5706.
26. Carlson RW, Moench SJ, Hammond ME, et al; NCCN HER2 Testing in Breast Cancer Task Force. HER2 testing in breast cancer: NCCN Task Force report and recommendations. J Natl Compr Canc Netw. 2006;4 Suppl 3:S1-S22; quiz S23-S24.
27. Ohlschlegel C, Zahel K, Kradolfer D, Hell M, Jochum W. HER2 genetic heterogeneity in breast carcinoma. J Clin Pathol. 2011;64(12): 1112-1116.
28. Vanden Bempt I, Van Loo P, Drijkoningen M, et al. Polysomy 17 in breast cancer: clinicopathologic significance and impact on HER-2 testing. J Clin Oncol. 2008;26(30):4869-4874.
29. Vranic S, Teruya B, Repertinger S, Ulmer P, Hagenkord J, Gatalica Z. Assessment of HER2 gene status in breast carcinomas with polysomy of chromosome 17. Cancer. 2011;117(1):48-53.